HLA-A and neoplasm: In a clinical study for patients with melanoma (69), WES of the tumor was conducted, validated by RNA-Seq and mutant (tumor) peptides were selected based on the patient’s HLA-A and -B alleles followed by production of long-peptides representing up to 20 neoepitopes per patient.